Floatz logo

DEXAMETHASONE

Indolent B-Cell Non-Hodgkin Lymphoma

Antengene CorporationSmall moleculePhase 2Active
BB
64/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
49/ 100
Competitive Position
89/ 100

Competitive context

12 Active assets in the Indolent B-Cell Non-Hodgkin Lymphoma cohort.

Asset / SponsorPhaseRating
Pembrolizumab
University of Washington
Phase 2BB
Epirubicin
University of Washington
Phase 2BB
(+)-VINCRISTINE
Fate Therapeutics
Phase 2BB
Polatuzumab Vedotin
University of Washington
Phase 2BB
cc-5013
Antengene Corporation
Phase 2BB

View all 15 →

Same molecule, other indications

DEXAMETHASONE is also rated in:

chemotherapy-induced toxicityDormant
A
Indicative ·
82 / 100
View asset →
adult acute lymphoblastic leukemiaDormant
BBB
Indicative ·
79 / 100
View asset →
B-cell childhood acute lymphoblastic leukemiaDormant
BBB
Indicative ·
78 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →